Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Benralizumab APFS functionality in severe asthma (GREGALE)
NCT02417961Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2015
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 3, open-label, single-arm trial of benralizumab in asthma, sponsored by AstraZeneca. Primary endpoints: Percentage of Patients/Caregivers Who Successfully Administered Benralizumab 30 mg Subcutaneously (SC) by Injection With an APFS at Home at Week 16, Percentage of Returned APFS Used to Administer Benralizumab at Home That Have Been Evaluated as Functional at Week 16 and 1 more. Started Apr 2015; status: completed.
02
Drugs
benralizumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02417961.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02417961.